biotech investing argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
biotech investing argenx Announces Results of Annual General Meeting and Board of Directors' Appointment of Karen Massey as Chief Executive Officer
biotech investing argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
biotech investing argenx Brings Neuromuscular Leadership to AAN 2026 with New Data Supporting Broader VYVGART Use Across MG and CIDP
biotech investing argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
biotech investing argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
biotech investing argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
biotech investing argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
